Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Stock analysts at William Blair lowered their Q3 2024 earnings estimates for Neumora Therapeutics in a report issued on Tuesday, May 7th. William Blair analyst M. Minter now anticipates that the company will earn ($0.37) per share for the quarter, down from their prior forecast of ($0.36). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Neumora Therapeutics' current full-year earnings is ($1.48) per share. William Blair also issued estimates for Neumora Therapeutics' FY2024 earnings at ($1.43) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($1.57) EPS.
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.34) earnings per share for the quarter, hitting the consensus estimate of ($0.34).
Several other analysts have also recently issued reports on the company. JPMorgan Chase & Co. upped their price objective on Neumora Therapeutics from $20.00 to $22.00 and gave the stock an "overweight" rating in a report on Monday, March 18th. Royal Bank of Canada reissued an "outperform" rating and issued a $31.00 price objective on shares of Neumora Therapeutics in a research note on Thursday, March 28th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Neumora Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $22.57.
Read Our Latest Research Report on Neumora Therapeutics
Neumora Therapeutics Trading Down 5.9 %
Shares of NMRA stock traded down $0.58 during trading hours on Friday, hitting $9.19. The stock had a trading volume of 292,661 shares, compared to its average volume of 608,098. Neumora Therapeutics has a one year low of $8.82 and a one year high of $21.00. The stock's 50-day moving average price is $13.00 and its two-hundred day moving average price is $14.01.
Institutional Investors Weigh In On Neumora Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of NMRA. Johnson & Johnson bought a new stake in shares of Neumora Therapeutics during the third quarter worth $12,870,000. FMR LLC bought a new stake in Neumora Therapeutics during the 3rd quarter valued at $79,360,000. Avidity Partners Management LP purchased a new position in shares of Neumora Therapeutics during the third quarter valued at $25,398,000. Soros Fund Management LLC purchased a new stake in Neumora Therapeutics in the third quarter worth about $141,000. Finally, Laurion Capital Management LP bought a new position in shares of Neumora Therapeutics during the third quarter valued at approximately $304,000. 47.65% of the stock is currently owned by hedge funds and other institutional investors.
About Neumora Therapeutics
(
Get Free Report)
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Further Reading
Before you consider Neumora Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.
While Neumora Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
